{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "95b04df8",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "from collections import Counter\n",
    "import spacy\n",
    "import pandas as pd\n",
    "\n",
    "# Load the spaCy language model\n",
    "nlp = spacy.load(\"en_core_web_sm\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "924ad803",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Read and parse the JSON file\n",
    "with open('tweets.json', 'r') as json_file:\n",
    "    data = json.load(json_file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "e6c79c89",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Initialize a counter for entity frequency\n",
    "entity_counter = Counter()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "e9f44260",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Process each tweet\n",
    "for tweet_data in data:\n",
    "    tweet = data[tweet_data]['tweet_text']\n",
    "    doc = nlp(tweet)\n",
    "    entities = [ent.text for ent in doc.ents]\n",
    "    entity_counter.update(entities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "819ffc7d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Counter({'Phase II': 9,\n",
       "         'CLL': 18852,\n",
       "         '73%': 7,\n",
       "         'https://t.co/eJ6m4QpC5P': 1,\n",
       "         '2': 403,\n",
       "         'AV': 2,\n",
       "         'MCL': 114,\n",
       "         'https://t.co/gg0G9At23N': 1,\n",
       "         '#AstraZenecas #': 1,\n",
       "         '#': 7114,\n",
       "         'Haematologica https://t.co/Z2kCLZaX0D': 1,\n",
       "         'https://t.co/6OuJptLCIN #lymsm': 1,\n",
       "         'AstraZeneca': 970,\n",
       "         'England': 15,\n",
       "         'Wales': 6,\n",
       "         '#oncology #drugapprovals': 1,\n",
       "         '#pharma #': 96,\n",
       "         'https://t.co/Sxve6NGGX3': 1,\n",
       "         'Superstar': 1,\n",
       "         'NICE': 8,\n",
       "         'FCR': 141,\n",
       "         'Ibrutinib': 227,\n",
       "         'yesterday': 29,\n",
       "         'UK': 194,\n",
       "         'Pirtobrutinib': 3,\n",
       "         '@cancertrials_ie @CllSociety': 1,\n",
       "         'https://t.co/murr3KPhsZ': 1,\n",
       "         'Optimal Management of High-Risk CLL': 1,\n",
       "         '19 March 2021': 1,\n",
       "         '7.00 pm - 8.30': 1,\n",
       "         '1': 241,\n",
       "         'Mumbai': 2,\n",
       "         '2 - Group Captain': 1,\n",
       "         'Pune\\n\\nChair': 1,\n",
       "         'Mumbai\\nModerator:': 1,\n",
       "         '@SWBH_RandD @Oncology_at_AZ': 1,\n",
       "         'today': 714,\n",
       "         'Thursday 18th March': 1,\n",
       "         'The National Institute for Health and Care Excellence': 1,\n",
       "         '17p': 200,\n",
       "         'https://t.co/ntYG8VLKyZ': 1,\n",
       "         'Thursday 18 March 2021': 1,\n",
       "         'https://t.co/nLoyYbepRA': 1,\n",
       "         '#pharma #lifesciences': 1,\n",
       "         '#CLL #leusm #': 658,\n",
       "         '#ClinicalResearchNews #': 1,\n",
       "         '#LifeSciencesNews #MedicalNews #': 1,\n",
       "         'PharmiwebNews': 1,\n",
       "         'Ireland': 50,\n",
       "         '@IPPOSI': 5,\n",
       "         'https://t.co/tW2zAInOlp': 1,\n",
       "         '@DaiichiSankyo': 1,\n",
       "         'Nilemdo': 1,\n",
       "         '1L #CLL': 8,\n",
       "         'Marc Auckland': 4,\n",
       "         'Sky News': 1,\n",
       "         '@bloodcancer_uk https://t.co/Sh0iIDgKel': 1,\n",
       "         'Malignancies': 10,\n",
       "         'https://t.co/NrxD4YK0zm': 1,\n",
       "         '#CLL #': 2715,\n",
       "         '@MDAndersonNews': 278,\n",
       "         'KTE': 3,\n",
       "         '@CHANEL': 1,\n",
       "         'Umbralisib': 26,\n",
       "         'Ublituximab': 30,\n",
       "         'the Treatment of Previously Untreated Mantle Cell Lymphoma': 2,\n",
       "         '#MCL #': 35,\n",
       "         'Solidarity': 8,\n",
       "         'Astra-Zeneca': 1,\n",
       "         'ICYMI': 7,\n",
       "         'TiP': 1,\n",
       "         'KRT-232': 1,\n",
       "         'LYMSM': 4,\n",
       "         'Argentina': 2,\n",
       "         'Janssen Vaccines &': 1,\n",
       "         'Prevention B.V.': 1,\n",
       "         'Pharma B.V.': 1,\n",
       "         '3': 440,\n",
       "         'AstraZeneca AB': 1,\n",
       "         '4': 179,\n",
       "         'Amgen Inc.': 4,\n",
       "         'Apremilast\\nLanadelumab\\nAbatacept-remdesivir-infliximab-mesilato de cenicriviroc': 1,\n",
       "         'Maria': 1,\n",
       "         'FDA': 1281,\n",
       "         '2013': 26,\n",
       "         'Ibrutinib FDA': 1,\n",
       "         '2017': 168,\n",
       "         '2020': 118,\n",
       "         'Brexucarbatagene Autoleucel FDA': 1,\n",
       "         '#lymphoma #': 352,\n",
       "         'BTK': 721,\n",
       "         'https://t.co/klsjuwWfDM': 1,\n",
       "         '17P': 8,\n",
       "         'TGTherapeutics': 2,\n",
       "         'https://t.co/l7qRcv0uDS': 1,\n",
       "         'Rituximab': 221,\n",
       "         'primario de eficacia en': 1,\n",
       "         'Physician Views Preview': 1,\n",
       "         'US': 145,\n",
       "         'AZN': 87,\n",
       "         'https://t.co/m89J49LBfC': 1,\n",
       "         'CLL Research: Acalabrutinib': 1,\n",
       "         '@medivizor': 395,\n",
       "         'Mantle Cell Lymphoma Survival Likely Affected': 1,\n",
       "         'CALQUENCE Beneficial': 1,\n",
       "         '#calquence #CLL #': 1,\n",
       "         '#rarecancer #': 1,\n",
       "         '@LLSusa': 55,\n",
       "         '#TCTM21 #gvhdsm': 1,\n",
       "         'Mantle Cell Lymphoma Treatment Market': 1,\n",
       "         'Forecast Data': 1,\n",
       "         'In-Depth Analysis': 1,\n",
       "         'Forecast': 20,\n",
       "         '2021': 23,\n",
       "         '2028': 1,\n",
       "         'rel/ref CLL': 1,\n",
       "         'HTA ID:': 1,\n",
       "         '20063': 1,\n",
       "         'National Centre for Pharmacoeconomics': 1,\n",
       "         'Lesen Sie': 2,\n",
       "         'Beitrag': 2,\n",
       "         '#Arzt #': 1,\n",
       "         '#Immuntherapie #': 1,\n",
       "         '#Therapie #': 1,\n",
       "         'Dr Danilov': 1,\n",
       "         '@OHSUNews': 2,\n",
       "         'SLL': 399,\n",
       "         'Dr Graff': 1,\n",
       "         'recent years': 7,\n",
       "         'Calquence': 406,\n",
       "         'Calquence Meets Primary Efficacy Endpoint': 1,\n",
       "         'Chronic': 2003,\n",
       "         'Japan': 45,\n",
       "         '#digitalhealth': 1,\n",
       "         'Lyfebulb': 1,\n",
       "         '#leusm https://t.co/oYihNdET4I': 1,\n",
       "         'Imbruvica': 362,\n",
       "         '| @AstraZeneca \\nhttps://t.co/m89J49LBfC': 1,\n",
       "         'Imbruvica https://t.co/AAQF9Btz5m': 1,\n",
       "         'https://t.co/1oki6GxPjP': 1,\n",
       "         'News| Acalabrutinib': 1,\n",
       "         'AMMHémato': 1,\n",
       "         'chez les': 2,\n",
       "         'd’une': 2,\n",
       "         'Findrugs': 1,\n",
       "         '#innovation #': 1,\n",
       "         '#hématologie #': 2,\n",
       "         'two': 160,\n",
       "         '#cancer': 85,\n",
       "         '#mantle cell': 1,\n",
       "         'Five': 6,\n",
       "         'Tuesday, January 26, 2021 - Roundup - MM&amp;M - Medical Marketing': 1,\n",
       "         'Calquence\\n\\n@Merck @statnews': 1,\n",
       "         '@moderna_tx @AstraZenecaUS @pfizer': 1,\n",
       "         'Johnson &': 17,\n",
       "         'Johnson': 8,\n",
       "         'AbbVie': 130,\n",
       "         '$AZN $JNJ $': 4,\n",
       "         'https://t.co/2n8KV2Mhza': 1,\n",
       "         'https://t.co/pbHwvaRtai': 1,\n",
       "         'CALQUENCE met Primary Efficacy Endpoint': 1,\n",
       "         'Trial Against Ibrutinib': 1,\n",
       "         'https://t.co/HSRYADWja1': 1,\n",
       "         'AZ': 64,\n",
       "         'The European Medicines Agency Review of Acalabrutinib': 2,\n",
       "         'the Treatment of Adult Patients': 2,\n",
       "         '#CALQUENCE Met Primary Efficacy Endpoint': 1,\n",
       "         'ChronicLymphocyticLeukemia': 157,\n",
       "         '#Refractory #': 1,\n",
       "         'ChronicLymphocyticLeukaemia': 15,\n",
       "         'https://t.co/3dDltqR7h2': 1,\n",
       "         'testa': 2,\n",
       "         'testa contro': 2,\n",
       "         'nella': 3,\n",
       "         'linfocitica': 2,\n",
       "         'https://t.co/0xCbBETtfM': 1,\n",
       "         'アストラゼネカのカルケンス': 1,\n",
       "         'Calquence®': 12,\n",
       "         'Monday': 17,\n",
       "         'Quick Takes': 1,\n",
       "         'Comirnaty': 1,\n",
       "         'Australia': 38,\n",
       "         'Hong Kong': 1,\n",
       "         'Albireo and Iterum': 1,\n",
       "         'Three years': 3,\n",
       "         'first': 553,\n",
       "         'second': 147,\n",
       "         'AbbVie’s': 2,\n",
       "         'BioPharma Dive': 2,\n",
       "         '#OncologyTopNews #': 1,\n",
       "         'Relapsed/Refractory CLL': 20,\n",
       "         'https://t.co/kBg8DCFFmB': 1,\n",
       "         '- Jain - - American Journal of Hematology - Wiley Online Library': 1,\n",
       "         'Topline': 1,\n",
       "         'CALQUENCE Met Primary Efficacy Endpoint': 4,\n",
       "         'BrainSights': 3,\n",
       "         '#strategy #': 19,\n",
       "         '#marketing': 19,\n",
       "         '#pharmaceutical': 9,\n",
       "         '#healthcare #': 17,\n",
       "         'https://t.co/ShghMeIhrE': 1,\n",
       "         '$AZN $': 6,\n",
       "         'JNJ': 18,\n",
       "         'https://t.co/m6YkcM0N8A': 1,\n",
       "         '$AZN $JNJ': 1,\n",
       "         '$JNJ $': 8,\n",
       "         'LLY': 4,\n",
       "         'https://t.co/rmkHEDOpXj': 1,\n",
       "         'Calquence Approved': 8,\n",
       "         'Eli Lilly': 2,\n",
       "         'CALQUENCE Met its Primary Efficacy Endpoint\\n\\nRelated Tickers': 1,\n",
       "         'AZN\\nRead': 2,\n",
       "         'https://t.co/2zmD10ekY5': 1,\n",
       "         'https://t.co/rYM3dexyjU': 1,\n",
       "         'Today': 177,\n",
       "         'https://t.co/bjLnjYzuBe': 1,\n",
       "         '#leukaemia #pharma #': 1,\n",
       "         '2L': 3,\n",
       "         'NEW YORK': 4,\n",
       "         'Einstufung': 5,\n",
       "         'Studiendaten': 4,\n",
       "         'Calquence zur Behandlung': 1,\n",
       "         'AKTIENCHECK': 1,\n",
       "         '▶ dpa-AFX': 2,\n",
       "         'Goldman': 2,\n",
       "         'FINANZTREFF': 2,\n",
       "         'https://t.co/cEd42RpVQ7': 1,\n",
       "         'https://t.co/qIzMgrqDqg': 1,\n",
       "         'ATRIAL FIBRILLATION': 1,\n",
       "         \"Calquence'\": 1,\n",
       "         'LiveSquawk': 1,\n",
       "         'AstraZeneca Plc - Calquence Met Primary Endpoint Against Ibrutinib\\nCalquence Met Primary Efficacy Endpoint': 2,\n",
       "         'Calquence Met Primary Endpoint': 1,\n",
       "         'ASTRAZENECA PLC - CALQUENCE MET PRIMARY ENDPOINT': 1,\n",
       "         'New CALQUENCE® Data': 1,\n",
       "         'Mantle Cell Lymphoma': 109,\n",
       "         '#CALQUENCE #': 1,\n",
       "         'CADTH': 4,\n",
       "         '1L': 42,\n",
       "         'Richters': 17,\n",
       "         'a quarter': 2,\n",
       "         '@AnnaSchuh3': 14,\n",
       "         'Bruton': 92,\n",
       "         'Leukemia': 139,\n",
       "         'Size': 12,\n",
       "         '2025': 11,\n",
       "         'https://t.co/fdzRB6KRVD': 1,\n",
       "         'https://t.co/fIrPpYDHI0': 1,\n",
       "         'Mit Acalabrutinib kam': 1,\n",
       "         'Dezember ein': 1,\n",
       "         'Bruton-Tyrosinkinase(BTK)-Hemmer auf den': 1,\n",
       "         'Markt': 1,\n",
       "         'Der Neuling': 1,\n",
       "         'das': 3,\n",
       "         '2014': 23,\n",
       "         'Leukämie': 14,\n",
       "         'https://t.co/XTWA2Bz5NB': 1,\n",
       "         'Global Acalabrutinib Market In-Depth Analysis Report': 1,\n",
       "         'Global Manufacturers\\xa0Analysis': 1,\n",
       "         'The PFS': 2,\n",
       "         'obinutuzumab/chlorambucil': 4,\n",
       "         'Seymour': 8,\n",
       "         'Europa': 15,\n",
       "         'prima': 5,\n",
       "         'quanto nella malattia': 1,\n",
       "         'refrattaria': 3,\n",
       "         'https://t.co/R1CPilGRTH': 1,\n",
       "         'https://t.co/W83AqqbUX8 CALQUENCE': 2,\n",
       "         'CALQUENCE': 218,\n",
       "         '535': 27,\n",
       "         'CALQUENCE+obinutuzumab': 26,\n",
       "         '90%': 45,\n",
       "         'CI': 47,\n",
       "         '0.06': 26,\n",
       "         'BM': 11,\n",
       "         'Rai III': 1,\n",
       "         '️hapto': 1,\n",
       "         'Tx': 20,\n",
       "         'Durvalumab': 3,\n",
       "         'https://t.co/l6wzhD0nPv': 1,\n",
       "         'Zanubrutinib': 33,\n",
       "         'Ian Flinn': 15,\n",
       "         'Condition Summary: Primary Central Nervous System Lymphoma': 1,\n",
       "         'PCNSL': 1,\n",
       "         'Health Technology Assessments': 1,\n",
       "         'sull’utilizzo di #': 1,\n",
       "         'della leucemia linfatica cronica': 1,\n",
       "         'con risultati significativi': 1,\n",
       "         'MRD': 379,\n",
       "         'Francesca Romana Mauro': 1,\n",
       "         'Comparing': 3,\n",
       "         '17%': 6,\n",
       "         '762': 2,\n",
       "         '2nd': 65,\n",
       "         '25.9 months': 2,\n",
       "         'Phase 2 #': 1,\n",
       "         'an average of 22 months': 1,\n",
       "         'アストラゼネカのアカラブルチニブ（Calquence®': 5,\n",
       "         '12/17': 1,\n",
       "         'アストラゼネカのアカラブルチニブ（Calquence®）、4つの試験データによって、慢性リンパ性白血病の患者さんの心血... https://t.co/UAxtcYBcaN': 1,\n",
       "         'アストラゼネカのアカラブルチニブ（Calquence(R)）、4つの試験データによって、慢性リンパ性白血病の患者さんの心血管安全性プロファイルを評価': 1,\n",
       "         '2x': 65,\n",
       "         '#ad https://t.co/613omF99rh': 1,\n",
       "         'AZN LR OP Multiple': 1,\n",
       "         'Oncology': 4,\n",
       "         'Tagrisso': 6,\n",
       "         'Lynparza, Calquence, Enhertu': 1,\n",
       "         'Imfinzi': 8,\n",
       "         'WHO Solidarity Trials': 1,\n",
       "         'Investigación 🔎': 1,\n",
       "         'linfocítica crónica @AstraZenecaES': 2,\n",
       "         'https://t.co/c60KOMIBJt': 2,\n",
       "         '🔎 Los datos de #': 1,\n",
       "         'https://t.co/1bPqyNA0km': 1,\n",
       "         'Kinumpirma ng Department of Health': 1,\n",
       "         'gagamitin sa World Health Organization': 1,\n",
       "         'only seven': 1,\n",
       "         'https://t.co/w4nltTQFJF': 1,\n",
       "         'gagamitin sa': 2,\n",
       "         '12': 112,\n",
       "         'WHO': 5,\n",
       "         'Calquence\\nhttps://t.co/8JwlIjSHTd': 1,\n",
       "         '5': 111,\n",
       "         'Avigan bilang gamot sa': 1,\n",
       "         'sa Pilipinas': 1,\n",
       "         'gamot kontra COVID-19': 1,\n",
       "         '@WHO': 8,\n",
       "         'sa mga gamot': 1,\n",
       "         'kasama sa': 1,\n",
       "         'Nagbigay': 1,\n",
       "         'Maria Rosario Vergeire': 2,\n",
       "         'https://t.co/BogahKfYMH': 1,\n",
       "         'Acalabrutinib': 7,\n",
       "         'bilang bahagi': 1,\n",
       "         'solidarity': 4,\n",
       "         'sa paghanap ng gamot': 1,\n",
       "         'para sa COVID-19': 1,\n",
       "         'World Health Organization': 4,\n",
       "         '阿卡替尼 孟加拉耀品国际首仿': 1,\n",
       "         'https://t.co/PkC83TF1kq': 1,\n",
       "         'Los datos de Calquence de 4': 1,\n",
       "         '@CALQUENCE': 3,\n",
       "         'all day': 7,\n",
       "         '#ad https://t.co/o9G2s6XEMh': 1,\n",
       "         'https://t.co/3vVU2IFbFi': 2,\n",
       "         'https://t.co/W83AqqbUX8 Learn': 7,\n",
       "         'year': 49,\n",
       "         'Learn': 48,\n",
       "         'ASH': 194,\n",
       "         'Dr Michael Wang': 2,\n",
       "         '#ad https://t.co/koo80IGjvP': 1,\n",
       "         'Leucemia linfatica': 1,\n",
       "         'monoterapia': 6,\n",
       "         'l’ottimo': 1,\n",
       "         \"nell'ambito\": 1,\n",
       "         'Paolo': 2,\n",
       "         'Acalabrutinib+R-CHOP': 1,\n",
       "         'ND #': 1,\n",
       "         '#ASH20 https://t.co/IF9eYVa8': 1,\n",
       "         'Early Intervention With Acalabrutinib in Patients With High Risk CLL': 1,\n",
       "         '#pharma': 9,\n",
       "         'Monday 11 January 2021': 1,\n",
       "         'https://t.co/QRGsgACUdd https://t.co/IDZTWq5Bhk': 1,\n",
       "         'Targeted\\xa0Oncology https://t.co/xwPSwP0ij8': 1,\n",
       "         \"Calquence, BeiGene's\": 12,\n",
       "         'Brukinsa': 18,\n",
       "         '#ad https://t.co/DljdCKTD7E https://t.co/aQD1ULX1AC': 1,\n",
       "         'Management of Waldenström Macroglobulinemia': 1,\n",
       "         '#AstraZeneca #': 5,\n",
       "         'Brown': 22,\n",
       "         'https://t.co/43pVoOkpdi': 1,\n",
       "         '#leusm #': 590,\n",
       "         '#news #pharma': 2,\n",
       "         '#biotech #lifesciences #': 3,\n",
       "         'four': 51,\n",
       "         '#news #pharma #': 14,\n",
       "         'ASH2020': 41,\n",
       "         'Day 3': 4,\n",
       "         '#ROR1inhibitor #MDM2inhibitor #': 1,\n",
       "         '#acalabrutinib #zanubritinib #': 1,\n",
       "         'the Treatment of Relapsed or': 4,\n",
       "         'Refractory Autoimmune Hemolytic Anemia in Patients With Chronic': 1,\n",
       "         'contra': 14,\n",
       "         'linfocítica crónica': 18,\n",
       "         'Unión Europea': 3,\n",
       "         'https://t.co/dmm83g8Osj': 1,\n",
       "         '#ChronicLymphocyticLeukaemia https://t.co/4HC742Om8': 2,\n",
       "         'New CALQUENCE': 9,\n",
       "         'cll': 140,\n",
       "         'venetoclax+obinatuzumab': 1,\n",
       "         '#ASH2020 https://t.co/zpspQNy8y1': 1,\n",
       "         'CARAMEL': 1,\n",
       "         '#acalabrutinib #': 11,\n",
       "         'II': 54,\n",
       "         'CALQUENCE Data Across': 2,\n",
       "         'https://t.co/oGzpJRnaOf': 1,\n",
       "         'Three Years': 18,\n",
       "         'FiercePharma': 13,\n",
       "         '#pharmatopnews #': 1,\n",
       "         'https://t.co/gBB1X0TTK1': 1,\n",
       "         'MCL https://t.co/xuH2beSMTw': 1,\n",
       "         'MD': 599,\n",
       "         'MPH': 13,\n",
       "         '2947 Phase 2 Study': 1,\n",
       "         'Hematology': 83,\n",
       "         'Shows Long-Term Efficacy and': 1,\n",
       "         '#ad https://t.co/kpqsMVmGLQ': 1,\n",
       "         'Lymphoma': 277,\n",
       "         '@AstraZeneca': 3,\n",
       "         'Less Than 1%': 1,\n",
       "         'https://t.co/bDMcZaWJHo': 1,\n",
       "         'CV': 2,\n",
       "         'https://t.co/fpte97uDSd': 1,\n",
       "         'MCL https://t.co/JvHjWIyvfe': 1,\n",
       "         'ACE-LY-004 Phase II': 1,\n",
       "         'Calquence - https://t.co/b8JIeZLF4S': 1,\n",
       "         'Day 2': 3,\n",
       "         'obinutuzumab https://t.co/MRBDl9AdeQ https://t.co/WLy1gaofTm': 1,\n",
       "         '︎': 3,\n",
       "         'https://t.co/FOL47mRFbO VIΛ': 1,\n",
       "         'ȘPĿIҬŚ FINΛNCIΛL': 3,\n",
       "         'MCL https://t.co/4DdzNkc7tO': 1,\n",
       "         'ACE': 27,\n",
       "         '#LatestPharmaNewsDec7 #': 1,\n",
       "         'LatestAstrazenecaNewsDec7 \\nhttps://t.co/GQHZzUJ6BW': 1,\n",
       "         'three years': 7,\n",
       "         '#refractory': 2,\n",
       "         '#mantlecelllymphoma $': 1,\n",
       "         'https://t.co/2Dd7CdJ1D8': 1,\n",
       "         '3 years': 9,\n",
       "         'Calquence and BeiGene’s': 1,\n",
       "         'https://t.co/nb6TYqWit2 #': 1,\n",
       "         '#competitiveintelligence #marketing': 1,\n",
       "         'https://t.co/5Cn35fMGtb': 1,\n",
       "         '📰 NEWS ALERT': 1,\n",
       "         'Efficacy': 19,\n",
       "         'Johnson - ASH': 1,\n",
       "         'Fintech Zoom': 1,\n",
       "         'ICO': 1,\n",
       "         'CALQUENCE Shows Long-Term Efficacy and': 7,\n",
       "         'Clive Zent': 5,\n",
       "         'StockMarket': 7,\n",
       "         '#mantlecelllymphoma     ': 1,\n",
       "         '#lymphoma': 43,\n",
       "         'ORR': 42,\n",
       "         '52%': 4,\n",
       "         'this year': 46,\n",
       "         'BTKis': 3,\n",
       "         'Nicola Lamanna': 1,\n",
       "         'https://t.co/fNEYyoTxW3': 1,\n",
       "         'Btk': 15,\n",
       "         'Christmas': 13,\n",
       "         'La Agencia Europea de Medicamentos': 1,\n",
       "         'EMA': 35,\n",
       "         'el tratamiento de leucemia linfocítica crónica': 1,\n",
       "         'de las': 1,\n",
       "         'La': 22,\n",
       "         'un': 81,\n",
       "         '#EMAapproval #': 1,\n",
       "         'https://t.co/2RBCWL3esZ https://t.co/vzIq0g7ih1': 1,\n",
       "         'https://t.co/obEDJId2i5 #': 1,\n",
       "         'Dec 7': 5,\n",
       "         'Paolo Ghia': 56,\n",
       "         'https://t.co/jPQIHPtq14': 1,\n",
       "         'ABIM #': 2,\n",
       "         'MedEd': 48,\n",
       "         'https://t.co/Xbm1MDi8nb': 1,\n",
       "         'https://t.co/Q8tBJWRh5Z': 1,\n",
       "         'https://t.co/b3IjDBRMXt #': 1,\n",
       "         'https://t.co/x2KyjOQZlA': 1,\n",
       "         'https://t.co/17s9RWLeha': 1,\n",
       "         'DOH': 3,\n",
       "         'Solidarity Trial': 1,\n",
       "         'Solidarity Therapeutics Trial': 2,\n",
       "         'Interferon': 10,\n",
       "         '#covid19 #SARSCOV2 #': 1,\n",
       "         '@Medivizor': 72,\n",
       "         'via @medivizor': 99,\n",
       "         'https://t.co/q96D7TjXSI': 1,\n",
       "         '#ad https://t.co/KaW6GaAICw https://t.co/cBv8eK4Wia': 1,\n",
       "         'kommt das': 1,\n",
       "         'Behandlungsoption': 1,\n",
       "         'https://t.co/xDWay9czSg': 1,\n",
       "         '#ad https://t.co/1tKQmxDMwR': 1,\n",
       "         'https://t.co/TXh0hAdz2e #': 1,\n",
       "         '👉🏼https://t.co/Zl0uXxvp4o': 1,\n",
       "         '👉🏼https://t.co/2RKhq2kkb0👈🏼': 1,\n",
       "         'https://t.co/S2SmE1Pygl': 1,\n",
       "         'Contribuez': 1,\n",
       "         'dans': 31,\n",
       "         'https://t.co/XnVrEkV7eG': 1,\n",
       "         'https://t.co/LhC0IinxYC': 1,\n",
       "         'https://t.co/PNKGq59aCR': 1,\n",
       "         '#ad https://t.co/G2Fg3POnie': 1,\n",
       "         'Calquence Fails Pair of': 10,\n",
       "         'https://t.co/6GuNjqcsvx': 1,\n",
       "         'UE': 1,\n",
       "         '2020年11月20日【アストラゼネカ｜日】『新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とする、アカラブルチニブ（Calquence': 1,\n",
       "         '呼吸不全未発症の生存患者の割合増加という主要評価項目を達成せず': 1,\n",
       "         'https://t.co/X1PEde9Spp': 1,\n",
       "         'Danilov &': 1,\n",
       "         'CLL &': 151,\n",
       "         '#WM': 2,\n",
       "         'EU': 278,\n",
       "         'https://t.co/ZfRmfV1CaW': 1,\n",
       "         '14-day': 1,\n",
       "         '1 to 3 days': 2,\n",
       "         '#COVID-19 https://t.co/NssVAZ1vEt': 1,\n",
       "         'https://t.co/5spf24Oa3A': 1,\n",
       "         'https://t.co/mUPuCji8bG': 1,\n",
       "         'Pembrolizumab Plus Acalabrutinib': 3,\n",
       "         'Platinum-Resistant Metastatic #': 1,\n",
       "         '📽': 6,\n",
       "         'ESMO20': 2,\n",
       "         '@sonpavde': 2,\n",
       "         'https://t.co/Z41GBayMa9': 1,\n",
       "         'https://t.co/MUsCSBQ2xR': 1,\n",
       "         'https://t.co/ai5FkMGUan #': 1,\n",
       "         '#ad https://t.co/6bmCbv2QBe': 1,\n",
       "         'https://t.co/OPcVZAmkG5 #MCL #lymsm #': 1,\n",
       "         'https://t.co/hX0lvkywy5': 1,\n",
       "         'Die Europäische Kommission': 1,\n",
       "         'Zulassung': 3,\n",
       "         'Behandlung von chronisch': 1,\n",
       "         'https://t.co/OpBRvSmVBf': 1,\n",
       "         '11/20': 1,\n",
       "         '新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第Ⅱ相試験': 1,\n",
       "         '#創薬 #': 1,\n",
       "         '#AI #': 4,\n",
       "         'Coronavirus': 12,\n",
       "         '新型コロナウイルス性呼吸器症状を有する入院患者さんを対象とするアカラブルチニブ（Calquence）CALAVI第Ⅱ相試験... https://t.co/Ow7fO1u2g6': 1,\n",
       "         'https://t.co/rbKwKoPKxV': 1,\n",
       "         'CALQUENCE®': 34,\n",
       "         'https://t.co/r0X9hV6lu8': 1,\n",
       "         '#ad https://t.co/u5RPyBDiXu https://t.co/lIjfV8mulj': 1,\n",
       "         'COVID-19 https://t.co/o59KhfbzC0': 1,\n",
       "         '#Acalabrutinib': 13,\n",
       "         '👉 https://t.co/GuoOZZsthw': 1,\n",
       "         'Safety Data': 1,\n",
       "         'https://t.co/KOFeTLi4vu': 1,\n",
       "         'CURE &': 1,\n",
       "         'CALQUENCE Connections': 2,\n",
       "         'November 21': 2,\n",
       "         '2PM': 3,\n",
       "         '#ad https://t.co/AwWPF5P1Uw': 1,\n",
       "         'https://t.co/LUQkyCKbpS': 1,\n",
       "         '#ad https://t.co/d7p49HxVT0': 1,\n",
       "         'BTK阻害薬acalabrutinib、慢性リンパ性白血病を適応にEUで承認取得': 1,\n",
       "         'CLL Treatment Research': 1,\n",
       "         'ASCEND': 63,\n",
       "         'BTKInhibitor': 1,\n",
       "         'https://t.co/mHoYUVp33s': 1,\n",
       "         'https://t.co/PFF4wchuFG': 1,\n",
       "         'https://t.co/fdHqNuMcQa': 1,\n",
       "         '#ad': 1,\n",
       "         '#ad https://t.co/YeEPWJi7Zo': 1,\n",
       "         'https://t.co/QpX0aHM2Jw': 1,\n",
       "         'https://t.co/MEUHtZquhl': 1,\n",
       "         '#ad https://t.co/qmsGJjYjxw https://t.co/C9fS13op8b': 1,\n",
       "         'アストラゼネカのアカラブルチニブ（Calquence(R)）EUにおいて、慢性リンパ性白血病の治療薬として承認取得': 2,\n",
       "         'Oncology News Update': 1,\n",
       "         'Oncology News': 3,\n",
       "         'https://t.co/LFwoRUAzFn': 1,\n",
       "         '®）EUにおいて、慢性リンパ性白血病の治療薬として承認取得': 1,\n",
       "         '11/17': 1,\n",
       "         '2020年11月17日【アストラゼネカ｜日】『アカラブルチニブ（Calquence': 1,\n",
       "         'https://t.co/ucdmgUqyxu': 1,\n",
       "         'https://t.co/ugOJpW32Rp': 1,\n",
       "         'BioSpace': 11,\n",
       "         'AZ社BTK阻害剤Calquenceは、入院患者に効果が認められず、コロナウイルスが引き起こす重篤な炎症応答へのBTK阻害剤の効果に疑問が持たれている。IL-6遮断薬の中止もあり、Eli Lilly社、Regeneron社、AZ社の抗体薬への期待が相対的に高まっている': 1,\n",
       "         'https://t.co/eNkelaGsec': 1,\n",
       "         '#エバリュエート #': 1,\n",
       "         'NOVITA': 1,\n",
       "         'NEL': 1,\n",
       "         'LEUCEMIA LINFATICA CRONICA - Approvato #Calquence': 1,\n",
       "         'Newsletter Xagena': 1,\n",
       "         'Medicina': 2,\n",
       "         'Xagena #': 1,\n",
       "         'Join CURE &': 1,\n",
       "         'Jeff Sharman': 191,\n",
       "         'Jim': 4,\n",
       "         'Becky': 1,\n",
       "         'MedLancr': 1,\n",
       "         'Reduce Mortality or Respiratory Failure': 1,\n",
       "         'la recomendación de la EMA': 1,\n",
       "         'Comisión Europea': 1,\n",
       "         'BioPharma': 1,\n",
       "         \"Costco - AstraZeneca's\": 1,\n",
       "         'Coronavirus Study': 3,\n",
       "         'Fintech Zoom - https://t.co/4Vh6i9S9UF @FintechZoom': 1,\n",
       "         'con la vacuna de la COVID-19': 1,\n",
       "         'la': 2,\n",
       "         'supervivencia sin progresión': 1,\n",
       "         'los pacientes': 1,\n",
       "         'OncoReporte': 1,\n",
       "         'AstraZenaca': 1,\n",
       "         '#clinicaltrials #pharma #': 1,\n",
       "         'https://t.co/oatqNMeiOm': 1,\n",
       "         'La UE': 6,\n",
       "         'COVID-19 https://t.co/tR4HCzw6p9': 1,\n",
       "         'One': 67,\n",
       "         '#pharmanews': 1,\n",
       "         'ElonMusk': 1,\n",
       "         'el tratamiento de adultos con leucemia': 1,\n",
       "         'ilacı koronavirüs': 2,\n",
       "         'koronavirüs hastalarının': 2,\n",
       "         'amaçlanan kan kanseri': 2,\n",
       "         'COVID_19': 1,\n",
       "         'ARD': 1,\n",
       "         'Covid': 15,\n",
       "         'NP': 2,\n",
       "         'https://t.co/suakSAViL0': 1,\n",
       "         'onder ziekenhuis': 1,\n",
       "         'https://t.co/Y7QNmOM5PD': 1,\n",
       "         'The European Union': 1,\n",
       "         '@EMA_News https://t.co/bDkVq0albN': 1,\n",
       "         'AstraZenca': 3,\n",
       "         'Meet its Primary Endpoint': 2,\n",
       "         'P-II Studies': 2,\n",
       "         'https://t.co/4SwJZEsdoE': 1,\n",
       "         '@Yahoo': 1,\n",
       "         'COVID-19': 20,\n",
       "         '11-12-2020': 1,\n",
       "         'https://t.co/8JwlIjSHTd': 4,\n",
       "         'the White House': 1,\n",
       "         'Otro': 2,\n",
       "         'NO funciona en evitar': 1,\n",
       "         'el posicionamiento de #': 1,\n",
       "         'в качестве потенциального метода': 2,\n",
       "         'ilaç şirketi AstraZeneca tarafından': 1,\n",
       "         'kan kanseri': 1,\n",
       "         'kullanılan Calquence': 1,\n",
       "         'korona': 1,\n",
       "         'olduğu açıklandı': 1,\n",
       "         'SONDAKIKA': 1,\n",
       "         'BioSpace https://t.co/q38xyvY6wD': 1,\n",
       "         'CALAVI Phase II': 3,\n",
       "         'https://t.co/SrcSOm7lDb': 2,\n",
       "         'Moderna': 1,\n",
       "         'para la leucemia': 1,\n",
       "         'linfocítica crónica  https://t.co/lSNumf738L': 1,\n",
       "         'Kristin Jensen': 1,\n",
       "         '$RHHBY $NVS $SNY $': 1,\n",
       "         'kan': 9,\n",
       "         'olduğu': 2,\n",
       "         'Medicago': 1,\n",
       "         'PhII/III': 1,\n",
       "         'https://t.co/Qfi1j64IVG': 1,\n",
       "         'Kanser': 5,\n",
       "         'https://t.co/vLlIRsRpEn\\n#': 1,\n",
       "         '#biotech #': 8,\n",
       "         'COVID19': 29,\n",
       "         'https://t.co/9jSZcmL7hJ': 1,\n",
       "         'CRS': 9,\n",
       "         'Biotech': 4,\n",
       "         'FPRX': 1,\n",
       "         'roughly 20%': 1,\n",
       "         'Phase 2': 7,\n",
       "         'ковида не оправдалась': 1,\n",
       "         'Small\\xa0Molecules https://t.co/MrdhwD6Ori': 1,\n",
       "         'https://t.co/OXdA2K2e5E #': 1,\n",
       "         'COVID-19 - https://t.co/QALAuDCaMK https://t.co/2V4uqnPUe7': 1,\n",
       "         '#Calquence': 2,\n",
       "         'Medicamento': 2,\n",
       "         'covid-19': 18,\n",
       "         'SFBN Feed:': 2,\n",
       "         '#BayArea #': 3,\n",
       "         'COVID-19 https://t.co/E1hk6OO6uH': 1,\n",
       "         'https://t.co/VgnlrmYWLz': 1,\n",
       "         'https://t.co/bb8v28s70i': 1,\n",
       "         'https://t.co/Md0aLh039H Update': 1,\n",
       "         'https://t.co/DC9zF468BR': 1,\n",
       "         'https://t.co/6AG4vdmRqf': 1,\n",
       "         '#Calquence disappoints': 1,\n",
       "         '$AZN #': 8,\n",
       "         'Après Novartis': 1,\n",
       "         'la semaine dernière': 1,\n",
       "         \"c'est désormais\": 1,\n",
       "         \"d'AstraZeneca qui\": 1,\n",
       "         'Did Not Meet Primary Endpoint': 1,\n",
       "         'AstraZeneca Announced Calavi Phase Ii Trials for Calquence in Patients Hospitalised With Respiratory Symptoms': 1,\n",
       "         'Did Not Meet Primary Endpoint\\n\\nRelated': 1,\n",
       "         'El fármaco': 3,\n",
       "         'contra la leucemia calquence': 1,\n",
       "         'Astrazeneca': 9,\n",
       "         'los ensayos': 1,\n",
       "         'AstraZeneca Plc': 3,\n",
       "         'Thursday': 23,\n",
       "         'FinancialPersonal': 1,\n",
       "         'COVID-19 https://t.co/oJIhIIKdFS': 1,\n",
       "         'The European Commission': 8,\n",
       "         'https://t.co/wEgFGEEhwu\\n#': 1,\n",
       "         'TUMORI': 2,\n",
       "         'LEUCEMIA LINFATICA CRONICA': 5,\n",
       "         'LA COMMISSIONE': 1,\n",
       "         'https://t.co/tPMvNlXCJJ': 1,\n",
       "         '#comitatoimalatiinvisibili #': 4,\n",
       "         '#comitatoimionlus #': 3,\n",
       "         '#ChronicLymphocyticLeukaemia $': 3,\n",
       "         'AZ’s Calquence': 9,\n",
       "         'LA CE': 1,\n",
       "         'para la': 5,\n",
       "         'el linfoma linfocítico pequeño': 1,\n",
       "         'Combinado': 1,\n",
       "         'el riesgo de progresión de enfermedad o muerte': 1,\n",
       "         'Europe': 74,\n",
       "         'https://t.co/sT6RLUGiOT': 1,\n",
       "         '#leusm  ': 12,\n",
       "         '😶': 1,\n",
       "         '@Nasdaq': 1,\n",
       "         'Europa https://t.co/cRBFtXG0es': 1,\n",
       "         'Salud de @Notimex  https://t.co/50siJTwS2x': 1,\n",
       "         'pembrolizumab vs pembrolizumab &': 3,\n",
       "         'UroToday &gt': 3,\n",
       "         '@AmericanCancer @TiansterZhang @MRHarrisonMD': 3,\n",
       "         'Venetoclax': 537,\n",
       "         'obinutuzumab': 226,\n",
       "         'Zdravilo Calquence': 1,\n",
       "         'odobreno za': 1,\n",
       "         '@ASTRAZENECAUK': 1,\n",
       "         'nuova': 3,\n",
       "         'sia': 1,\n",
       "         'sia dopo ricaduta': 1,\n",
       "         'AMM': 1,\n",
       "         'Terapia': 4,\n",
       "         'Europa https://t.co/TRqsGUerUm': 1,\n",
       "         'nella malattia': 1,\n",
       "         'https://t.co/KiOjg4LE39': 1,\n",
       "         '1.4': 1,\n",
       "         'PAP Support': 1,\n",
       "         '#LatestPharmaNewsNov9 #': 1,\n",
       "         'https://t.co/avIAqF4wqr': 1,\n",
       "         'Remdesivir': 7,\n",
       "         'Samiran Panda': 1,\n",
       "         'the European Union': 5,\n",
       "         '#leukaemia #': 86,\n",
       "         'Cancer': 46,\n",
       "         'FREE': 26,\n",
       "         '#cancernews #': 1,\n",
       "         'Calquence https://t.co/gGhPz9jTzu': 1,\n",
       "         \"Calquence OK'd\": 2,\n",
       "         'European': 41,\n",
       "         'US Market News': 2,\n",
       "         'Nasdaq News - https://t.co/fWUdbvKdVL': 1,\n",
       "         'AstraZeneca Announced Calquence Approved': 2,\n",
       "         'the Eu for the Treatment of Chronic': 1,\n",
       "         'the Treatment of Chronic': 7,\n",
       "         'European Union': 1,\n",
       "         'CCL': 3,\n",
       "         '#AZN Calquence': 1,\n",
       "         '#oncology #': 165,\n",
       "         '#pharma $': 1,\n",
       "         'singlestockETPs\\nhttps://t.co/66gsMtTizU': 1,\n",
       "         'Pembrolizumab': 29,\n",
       "         '#bladdercancer #': 2,\n",
       "         'Platinum-Resistant Metastatic Urothelial': 2,\n",
       "         'Safety Study Supports Acalabrutinib Alone or in Combination for CLL': 1,\n",
       "         '@EngIPM': 2,\n",
       "         'Richard Furman': 80,\n",
       "         'M.D': 1,\n",
       "         'PrecisionMedicine': 8,\n",
       "         'Versus Zanubrutinib': 1,\n",
       "         'American Society of Hematology': 86,\n",
       "         'https://t.co/Pfxw71m0h9': 1,\n",
       "         'at least one': 94,\n",
       "         '60%': 1,\n",
       "         'PD': 27,\n",
       "         '11%': 4,\n",
       "         '28.6': 1,\n",
       "         '22.0': 1,\n",
       "         'PFS': 53,\n",
       "         '1/3': 4,\n",
       "         '36': 14,\n",
       "         '#lymsm #': 225,\n",
       "         'Sakigake-Designated HAE Med Berotralstat': 2,\n",
       "         'AZ’s Acalabrutinib Clear PAFSC Review OrphanPacific’s': 1,\n",
       "         'https://t.co/07SVDclr7q': 1,\n",
       "         '#CLL #Ibrutinib #': 4,\n",
       "         '@RichardFurmanMD https://t.co/aGOKuhaL3W': 1,\n",
       "         'CI Andy': 1,\n",
       "         'CNS': 23,\n",
       "         'https://t.co/YWghVa35x3、酸性にしないと溶けないのでコカ・コーラに溶かすって草不可避': 1,\n",
       "         'rituximab': 200,\n",
       "         'a Phase Ib/II': 1,\n",
       "         'ICMR': 20,\n",
       "         'WHO Solidarity': 4,\n",
       "         '@ChandnaHimani': 6,\n",
       "         'Kombination': 5,\n",
       "         'Obinutuzumab zeigt': 1,\n",
       "         'Vergleich zu anderen': 1,\n",
       "         'Frontline-Behandlungen': 1,\n",
       "         'Fludarabin nicht': 1,\n",
       "         'https://t.co/emB9IkutHU': 1,\n",
       "         'Try Calquence': 1,\n",
       "         '200': 11,\n",
       "         '4 months': 1,\n",
       "         '#icmr #': 1,\n",
       "         '#covid19 #': 11,\n",
       "         '#cdsco': 1,\n",
       "         '#remdesivir #': 1,\n",
       "         'Calquence https://t.co/AOQm5shPsd': 1,\n",
       "         'AZ’s': 1,\n",
       "         'PAFSC Review': 1,\n",
       "         'Oct. 30': 1,\n",
       "         'OrphanPacific': 1,\n",
       "         'the World Health Organization': 3,\n",
       "         '2019': 182,\n",
       "         'MT': 10,\n",
       "         'Oct 7, 2020]': 1,\n",
       "         '@LLSusa &': 3,\n",
       "         '#CLLsm #leusm #': 11,\n",
       "         'COVID19nCancer': 1,\n",
       "         'AstraZeneca Pharma India': 5,\n",
       "         'India': 42,\n",
       "         'Oct 21': 4,\n",
       "         'カルケンス（一般名：アカラブルチニブ）」が30日開催予定の第二部会にて「再発または難治性の慢性リンパ性白血病': 1,\n",
       "         'SOLIDARITY': 2,\n",
       "         'IV': 8,\n",
       "         'Bemcentinib Capsule': 1,\n",
       "         'AXL': 5,\n",
       "         'B1': 13,\n",
       "         'Two': 53,\n",
       "         'two weeks': 6,\n",
       "         '1Bn': 1,\n",
       "         '#remdesivir 😲\\n2': 1,\n",
       "         'cancer drug': 12,\n",
       "         '#COVID19 https://t.co/bIkImDLTJs': 1,\n",
       "         'https://t.co/wqjckSh6BX': 1,\n",
       "         'Friday': 33,\n",
       "         'DoktorNews': 1,\n",
       "         'Read': 3,\n",
       "         'https://t.co/tlTVZ4LpgC\\n👉YouTube-https://t.co/6BEykx8TIS\\n': 1,\n",
       "         '#India #AstraZenecaPharma #': 1,\n",
       "         'Daycosecurities https://t.co/vMB5Ueasl8': 1,\n",
       "         '#astrazenecanews #acalabrutinibcapsules': 1,\n",
       "         '60,950': 1,\n",
       "         '63.4 लाख': 1,\n",
       "         'में खरीदेगी': 1,\n",
       "         'AstraZeneca Pharma': 7,\n",
       "         'October 21': 9,\n",
       "         '#stockmarket #': 1,\n",
       "         '#finance': 1,\n",
       "         '#financenewsdaily #': 1,\n",
       "         '#india': 1,\n",
       "         'Exclusive Morning Market News &': 1,\n",
       "         'Update': 2,\n",
       "         'Drugs Controller': 1,\n",
       "         'March 12': 1,\n",
       "         '100': 27,\n",
       "         'a few #StocksToWatch': 2,\n",
       "         'CAPIOT Software': 2,\n",
       "         '$6.34 m': 2,\n",
       "         '#... #': 1,\n",
       "         'frontpage_app https://t.co/ZWrZzX1Djd': 1,\n",
       "         'https://t.co/hpLXR0Dz8r': 1,\n",
       "         'KPMG': 1,\n",
       "         'October 8': 1,\n",
       "         'UPL': 1,\n",
       "         'Mauritius - UPL Corporation': 1,\n",
       "         'October 21, 2020\\nAlert: Calquence Medicine Is Used To Treat Adults With Mantle Cell': 1,\n",
       "         'Launch Calquence': 1,\n",
       "         'October 21, 2020': 1,\n",
       "         '#Pharmaceutical': 1,\n",
       "         'ASTRAZEN - Launch Of Acalabrutinib 100Mg Capsules': 1,\n",
       "         'CoronaVirus': 1,\n",
       "         'चाहता': 1,\n",
       "         'पैनल': 1,\n",
       "         'CoronaUpdates': 1,\n",
       "         '#letsBeatCorona #': 1,\n",
       "         'IndiaFightsCorona': 1,\n",
       "         '#coronavirusindia\\nhttps://t.co/RKoQzwYv3j': 1,\n",
       "         'ETIndustryNews': 1,\n",
       "         '#YoSoyJabali': 1,\n",
       "         '\\u2066@ICMRDELHI\\u2069': 1,\n",
       "         '#Covid-19': 1,\n",
       "         'https://t.co/7fFdSZXi55': 1,\n",
       "         'https://t.co/ie6LhZnlYd': 1,\n",
       "         'https://t.co/gcwXoOtYRh': 1,\n",
       "         'Indian Council of Medical Research': 1,\n",
       "         'the World Heath Organization’s': 1,\n",
       "         'MCL  https://t.co/RWNWKsAMdD': 1,\n",
       "         'ICMR  ': 1,\n",
       "         '@ETHealthWorld App': 1,\n",
       "         'https://t.co/LgSxxma0As': 1,\n",
       "         'ETHealthworld': 3,\n",
       "         '#ICMR #Dexamethasone #': 1,\n",
       "         'ThePrint': 2,\n",
       "         'https://t.co/kxXbva00S8': 1,\n",
       "         'cllsm': 1,\n",
       "         'a few weeks': 2,\n",
       "         '适用于套细胞淋巴瘤患者，Acalabrutinib是一种激酶抑制剂，通过阻断肿瘤细胞复制和转移所需的酶发挥疗效。作为第二代BTK抑制剂，相比于第一代的BTK抑制剂伊布替尼，副作用更低。 https://t.co/P9MEjeTKYq': 1,\n",
       "         '适用于套细胞淋巴瘤患者，Acalabrutinib是一种激酶抑制剂，通过阻断肿瘤细胞复制和转移所需的酶发挥疗效。作为第二代BTK抑制剂，相比于第一代的BTK抑制剂伊布替尼，副作用更低。': 1,\n",
       "         '适用于套细胞淋巴瘤患者，Acalabrutinib是一种激酶抑制剂，通过阻断肿瘤细胞复制和转移所需的酶发挥疗效。作为第二代BTK抑制剂，相比于第一代的BTK抑制剂伊布替尼，副作用更低。 https://t.co/WFYCvmUUC9': 1,\n",
       "         'https://t.co/mpaCAFP9AC #': 1,\n",
       "         'Najít': 1,\n",
       "         '#SolidarityTrial #': 1,\n",
       "         '#CZECRIN #': 1,\n",
       "         '#SUKL #remdesivir #': 1,\n",
       "         'Medscape Hematology-Oncology': 3,\n",
       "         '#lymphomahub https://t.co/x01M51QIyN': 1,\n",
       "         'a Systematic Review': 3,\n",
       "         '1st': 110,\n",
       "         'RESONATE-2 &': 1,\n",
       "         '↔️': 1,\n",
       "         '⏩ U-MRD': 1,\n",
       "         '11/2020': 4,\n",
       "         'Proton Pump Inhibitor': 3,\n",
       "         'Healthy Subjects': 4,\n",
       "         'NCT04488016': 1,\n",
       "         'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請': 4,\n",
       "         'BTK阻害薬acalabrutinibがCLL/SLLを対象に申請：がんナビ\\n#': 1,\n",
       "         'SLLを対象に申請': 1,\n",
       "         'El Instituto Nacional del Cáncer': 1,\n",
       "         'para ayudar': 2,\n",
       "         'el COVID-19': 1,\n",
       "         '#COVID19 #': 40,\n",
       "         'el estudio': 1,\n",
       "         '@Notimex': 1,\n",
       "         'Amy Burd': 1,\n",
       "         'PhD @LLSusa &': 1,\n",
       "         'John C. Byrd': 13,\n",
       "         'COVID-19 - Healio https://t.co/1oHiaow5BJ': 1,\n",
       "         'CALQUENCE Drug Profile': 2,\n",
       "         '#ClinicalTherapeutics #Physicians': 1,\n",
       "         'acalabrutinib drug': 1,\n",
       "         'Briton Tyrosine Kinase': 1,\n",
       "         '@FLOTUS': 1,\n",
       "         'WeLoveTrump': 1,\n",
       "         '@OncNursingNews': 3,\n",
       "         'Hydroxychloroquine': 1,\n",
       "         'Jakafi': 1,\n",
       "         'Ilaris': 1,\n",
       "         'Mavrilimumab': 1,\n",
       "         'Decepticon': 1,\n",
       "         'Randomized Trial of Acalabrutinib -': 1,\n",
       "         'Ph.D.': 6,\n",
       "         'Caluquence': 1,\n",
       "         'Keep Inspiring\" campaign!🎨🖌️': 1,\n",
       "         '#keepinspiring': 1,\n",
       "         '#newcampagintheme #': 1,\n",
       "         '#interestingmarketing': 1,\n",
       "         '#q2 #': 1,\n",
       "         '#leukemiamarket #': 3,\n",
       "         'September': 37,\n",
       "         '#Leukemia and': 1,\n",
       "         'Lymphoma AwarenessMonth': 1,\n",
       "         'ClinicalTrial': 211,\n",
       "         'Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect': 1,\n",
       "         'Acalabrutinib Tablet': 1,\n",
       "         'Protonpump Inhibitor Effect': 1,\n",
       "         'Randomized Trial of Acalabrutinib https://t.co/kIjnP9UMSX': 1,\n",
       "         '@KingsCollegeNHS &amp': 1,\n",
       "         '@UHSFT': 1,\n",
       "         'RichtersSyndrome': 6,\n",
       "         '11/16': 3,\n",
       "         '@AnnaSchuh3 @tobyeyre82': 1,\n",
       "         '@CRCTU': 4,\n",
       "         'https://t.co/NVTHDy8sej': 1,\n",
       "         'https://t.co/f1ksnRFLUe': 1,\n",
       "         'Michael Wang': 4,\n",
       "         'MD @michaelwangmd @MDAndersonNews Durable': 1,\n",
       "         '9': 80,\n",
       "         'Anna': 2,\n",
       "         'Nicole': 1,\n",
       "         'Dr Rafferty': 1,\n",
       "         '@CRCTU @AnnaSchuh3': 1,\n",
       "         'UPLC-MS/MS': 2,\n",
       "         'JPBA  https://t.co/xftxi4xax4': 1,\n",
       "         'bloodcancerawarenessmonth': 4,\n",
       "         'Jennifer Woyach': 77,\n",
       "         'https://t.co/LQnpqdJCLd': 1,\n",
       "         'A Phase 2 Trial of Acalabrutinib': 2,\n",
       "         'Relapsed/Refractory Primary': 2,\n",
       "         'Condition Summary: Lymphoma': 3,\n",
       "         '#DLBCL #': 14,\n",
       "         '#leusm': 125,\n",
       "         '$APTO #': 1,\n",
       "         'PhD': 168,\n",
       "         '3rd': 11,\n",
       "         'Woyach': 29,\n",
       "         'the Role of Acalabrutinib': 2,\n",
       "         'https://t.co/uq0qTyN2qL': 1,\n",
       "         'CONGRESS': 46,\n",
       "         '#SOHO2020': 12,\n",
       "         'https://t.co/a18Y9JBNDR': 1,\n",
       "         '@SocietyofHemOnc #SOHO2020 -': 1,\n",
       "         'WCC': 1,\n",
       "         '60': 21,\n",
       "         '102': 2,\n",
       "         'Teamhaem': 1,\n",
       "         'Ghia': 7,\n",
       "         'CHMP': 1,\n",
       "         'Trials in China': 1,\n",
       "         'IL-6': 3,\n",
       "         'Italy': 6,\n",
       "         'IL-1': 3,\n",
       "         'U.S.': 96,\n",
       "         'M 56': 1,\n",
       "         '8.4x16cm': 1,\n",
       "         'RCHOP/RDHAP': 1,\n",
       "         ...})"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entity_counter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "debf0c6d",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Sort entities by frequency in descending order\n",
    "sorted_entities = [(entity, freq) for entity, freq in entity_counter.most_common()]\n",
    "\n",
    "# Create a DataFrame for the results\n",
    "df = pd.DataFrame(sorted_entities, columns=['entity', 'frequency'])\n",
    "\n",
    "# Save the results to a CSV file\n",
    "df.to_csv('objective1.csv', index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "7a74e047",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "e7d92888",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "No model was supplied, defaulted to distilbert-base-uncased-finetuned-sst-2-english and revision af0f99b (https://huggingface.co/distilbert-base-uncased-finetuned-sst-2-english).\n",
      "Using a pipeline without specifying a model name and revision in production is not recommended.\n",
      "All PyTorch model weights were used when initializing TFDistilBertForSequenceClassification.\n",
      "\n",
      "All the weights of TFDistilBertForSequenceClassification were initialized from the PyTorch model.\n",
      "If your task is similar to the task the model of the checkpoint was trained on, you can already use TFDistilBertForSequenceClassification for predictions without further training.\n"
     ]
    }
   ],
   "source": [
    "\n",
    "import pandas as pd\n",
    "from transformers import pipeline\n",
    "\n",
    "# Load a pre-trained sentiment analysis model from Hugging Face Transformers\n",
    "sentiment_analyzer = pipeline(\"sentiment-analysis\")\n",
    "\n",
    "# Create a dictionary to store sentiment scores\n",
    "sentiment_scores = {}\n",
    "\n",
    "# Process each tweet\n",
    "i = 0\n",
    "\n",
    "for tweet_data in data:\n",
    "    i = i+1\n",
    "    if i<50:\n",
    "        author = data[tweet_data]['tweet_author']\n",
    "        tweet = data[tweet_data]['tweet_text']\n",
    "        sentiment = sentiment_analyzer(tweet)  # Analyze sentiment\n",
    "\n",
    "        # Store the sentiment score in the dictionary\n",
    "        sentiment_scores[author] = sentiment_scores.get(author, [])\n",
    "        sentiment_scores[author].append(sentiment[0]['label'])\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "731ccd51",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Hematopoiesis News': ['NEGATIVE'],\n",
       " 'Michael Wang, MD': ['NEGATIVE', 'NEGATIVE'],\n",
       " '1stOncology': ['NEGATIVE'],\n",
       " 'Toby Eyre': ['POSITIVE', 'NEGATIVE'],\n",
       " 'Lymphoma Hub': ['POSITIVE', 'NEGATIVE'],\n",
       " 'David Ledger': ['POSITIVE'],\n",
       " 'N Wales Cancer Forum': ['NEGATIVE'],\n",
       " 'European Pharmaceutical Review': ['NEGATIVE'],\n",
       " 'Graham Collins': ['POSITIVE'],\n",
       " 'CLL Ireland': ['POSITIVE', 'NEGATIVE'],\n",
       " 'Mice Ideas': ['POSITIVE'],\n",
       " 'Farooq A Wandroo': ['NEGATIVE'],\n",
       " 'Leukaemia Care': ['POSITIVE'],\n",
       " 'Helen Oram': ['NEGATIVE'],\n",
       " 'HealthWatch': ['NEGATIVE'],\n",
       " 'PHARMABOX.IN': ['POSITIVE'],\n",
       " 'Pharma Trader': ['POSITIVE'],\n",
       " 'Everything Pharma': ['POSITIVE'],\n",
       " 'IJPSonline': ['POSITIVE'],\n",
       " 'Iceberg Vision': ['POSITIVE'],\n",
       " 'PharmaTimes': ['POSITIVE'],\n",
       " 'Paperbirds_Hematology': ['NEGATIVE',\n",
       "  'NEGATIVE',\n",
       "  'NEGATIVE',\n",
       "  'NEGATIVE',\n",
       "  'NEGATIVE',\n",
       "  'NEGATIVE'],\n",
       " 'Pharma News': ['NEGATIVE'],\n",
       " 'pharmaphorum': ['NEGATIVE'],\n",
       " 'Lymphoma Papers': ['NEGATIVE', 'NEGATIVE'],\n",
       " 'Trip Database': ['NEGATIVE'],\n",
       " 'Osgood': ['NEGATIVE'],\n",
       " 'Thiago Carvalho': ['NEGATIVE'],\n",
       " 'Kartos Therapeutics': ['NEGATIVE'],\n",
       " 'Apoli Naria': ['NEGATIVE'],\n",
       " 'Cardio-Targets': ['NEGATIVE', 'NEGATIVE'],\n",
       " 'Jeff Sharman': ['POSITIVE'],\n",
       " 'IM Médico': ['NEGATIVE'],\n",
       " 'FirstWord Pharma': ['POSITIVE'],\n",
       " 'CancerNetwork®, Home of the Journal ONCOLOGY®': ['POSITIVE'],\n",
       " 'Tom Henry, MBA, RPh, CPh': ['NEGATIVE'],\n",
       " 'Medivizor': ['NEGATIVE'],\n",
       " 'mednetnews': ['NEGATIVE']}"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentiment_scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "e8035a28",
   "metadata": {},
   "outputs": [],
   "source": [
    "sentiment_author_list = []\n",
    "for author, sentiments in sentiment_scores.items():\n",
    "    for sentiment in sentiments:\n",
    "        sentiment_author_list.append([author, sentiment])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "4ea9fbe6",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert the sentiment scores dictionary to a DataFrame\n",
    "df = pd.DataFrame(sentiment_author_list)\n",
    "df.rename(columns = {0:'Entity',1:'Sentiment'}, inplace = True)\n",
    "# Save the results to a CSV file\n",
    "# \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "182a4fc1",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('sentiment_scores.csv')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
